Global scale Cerba Research combines a specialty laboratory foundation with a global network of 1000 labs and access to data from over 85 million patients, presenting a compelling proposition for CROs and pharma sponsors seeking comprehensive, consistently supported testing across all clinical trial phases.

Comprehensive capabilities The company offers end-to-end testing across oncology, virology, vaccine development, immunology, and cell and gene therapy, plus advanced analytics from next generation sequencing to spatial omics and bioinformatics, enabling cross-disease trial platforms and accelerated study timelines.

Data advantage With extensive patient data and rapid sequencing capacity (1000+ whole genomes per week), Cerba Research can support real-time analytics, biomarker discovery, and precision medicine trials, appealing to sponsors pursuing adaptive designs and portfolio-wide stratification.

Partnership appetite Recent strategic collaborations with Ozette Technologies, AgencyUK, and existing acquisitions indicate a readiness to co-develop tools, digital experiences, and integrated solutions, offering upsell opportunities in digital lab services and end-to-end trial enablement.

mid-market positioning With revenue in the $50M–$100M range and a mid-sized, globally capable profile, Cerba Research can target mid- to large-cap sponsors seeking a flexible, integrated partner to complement larger CROs, while offering competitive pricing and responsive service in niche testing domains.